Mignini Irene, Maresca Rossella, Ainora Maria Elena, Larosa Luigi, Scaldaferri Franco, Gasbarrini Antonio, Zocco Maria Assunta
CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy.
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy.
J Clin Med. 2023 Sep 12;12(18):5933. doi: 10.3390/jcm12185933.
Therapeutic options for inflammatory bowel diseases (IBD) have largely expanded in the last decades, both in Crohn's disease and ulcerative colitis, including multiple biological drugs targeting different inflammation pathways. However, choosing the best treatment and timing for each patient is still an undeniable challenge for IBD physicians due to the marked heterogeneity among patients and disease behavior. Therefore, early prediction of the response to biological drugs becomes of utmost importance, allowing prompt optimization of therapeutic strategies and thus paving the way towards precision medicine. In such a context, researchers have recently focused on cross-sectional imaging techniques (intestinal ultrasound, computed tomography, and magnetic resonance enterography) in order to identify predictive markers of response or non-response to biologic therapies. In this review, we aim to summarize data about imaging factors that may early predict disease behavior during biological treatment, potentially helping to define more precise and patient-tailored strategies.
在过去几十年中，炎症性肠病（IBD）的治疗选择有了很大扩展，无论是在克罗恩病还是溃疡性结肠炎方面，包括多种针对不同炎症途径的生物药物。然而，由于患者之间以及疾病行为存在显著异质性，为每位患者选择最佳治疗方法和时机对IBD医生来说仍是一项不可忽视的挑战。因此，生物药物反应的早期预测变得至关重要，这有助于及时优化治疗策略，从而为精准医学铺平道路。在这种背景下，研究人员最近聚焦于横断面成像技术（肠道超声、计算机断层扫描和磁共振肠造影），以识别生物治疗反应或无反应的预测标志物。在本综述中，我们旨在总结有关成像因素的数据，这些因素可能早期预测生物治疗期间的疾病行为，潜在地有助于制定更精确且针对患者的策略。
